These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9823424)

  • 1. Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
    Panday VR; ten Bokkel Huinink WW; Rosing H; Koopman FJ; Hillebrand MJ; Dubbelman RC; van Tellingen O; Schellens JH; Beijnen JH
    Anticancer Drugs; 1998 Sep; 9(8):665-73. PubMed ID: 9823424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
    Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
    Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Milandri C; Gentile A; Salzano E; Amadori D
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):22-8. PubMed ID: 8941407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
    Buzdar AU; Holmes FA; Hortobagyi GN
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
    Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
    Ellis GK; Gralow JR; Pierce HI; Williams MA; Livingston RB
    J Clin Oncol; 1999 May; 17(5):1407-12. PubMed ID: 10334525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
    Gianni L; Munzone E; Capri G; Fulfaro F; Tarenzi E; Villani F; Spreafico C; Laffranchi A; Caraceni A; Martini C
    J Clin Oncol; 1995 Nov; 13(11):2688-99. PubMed ID: 7595726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Casadei Giunchi D; Gentile A; Salzano E
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):19-23. PubMed ID: 8629031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
    Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
    Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
    Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Bourgeois H; Ferru A; Lortholary A; Delozier T; Boisdron-Celle M; Abadie-Lacourtoisie S; Joly F; Chieze S; Chabrun V; Gamelin E; Tourani JM
    Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
    Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
    J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
    Klaassen U; Wilke H; Weyhofen R; Harstrick A; Eberhardt W; Müller C; Korn M; Hanske M; Diergarten K; Seeber S
    Anticancer Drugs; 1998 Mar; 9(3):203-7. PubMed ID: 9625430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
    Tolcher AW; Gelmon KA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):28-32. PubMed ID: 7638639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
    Sparano JA; Speyer J; Gradishar WJ; Liebes L; Sridhara R; Mendoza S; Fry D; Egorin MJ
    J Clin Oncol; 1999 Mar; 17(3):880-6. PubMed ID: 10071279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.